NYSE American - Delayed Quote USD

Armata Pharmaceuticals, Inc. (ARMP)

2.7600

+0.2292

(+9.06%)

At close: April 26 at 3:56 PM EDT

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for ARMP

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?

Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

INVA Innoviva, Inc.

15.26

+1.80%

PHGE BiomX Inc.

0.3500

+4.17%

GNFT Genfit S.A.

3.4900

+2.35%

SYBX Synlogic, Inc.

1.8700

-1.06%

ANEB Anebulo Pharmaceuticals, Inc.

2.7036

+1.26%

ANTX AN2 Therapeutics, Inc.

2.3200

+1.75%

IPSC Century Therapeutics, Inc.

2.8800

-8.57%

ARDS Aridis Pharmaceuticals, Inc.

0.0650

0.00%

ELDN Eledon Pharmaceuticals, Inc.

2.0600

+1.98%

AEON AEON Biopharma, Inc.

5.07

+19.29%